Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trialJean Chastre, Tomas Hruby, Marc Bourgeois et al.|Critical Care|2022Cited by 93
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Alain Lepape, Hasan S. Jafri et al.|The Lancet Infectious Diseases|2021Cited by 88
Molecular quantification of bacteria from respiratory samples in patients with suspected ventilator-associated pneumoniaM. Clavel, Javier Yugueros-Marcos, Olivier Barraud et al.|Clinical Microbiology and Infection|2016Cited by 43
Enterobacterales carrying chromosomal AmpC β-lactamases in Europe (EuESCPM): Epidemiology and antimicrobial resistance burden from a cohort of 27 hospitals, 2020–2022Matteo Boattini, Corina Muşuroi, Gabriele Bianco et al.|International Journal of Antimicrobial Agents|2024Cited by 30
Shotgun metagenomics for microbiome and resistome detection in septic patients with urinary tract infectionOlivier Barraud, Philippe Vignon, Céline Ravry et al.|International Journal of Antimicrobial Agents|2019Cited by 29